Dose compliance of estramustine phosphate in neoadjuvant chemohormonal therapy combined with degarelix acetate predicts the biochemical recurrence in patients with very high-risk prostate cancer who underwent robot-assisted radical prostatectomy.
Takanari KambeToshinari YamasakiAkihiro YamamotoAkihiko NagoshiTasuku FujiwaraYuta MineHiroki HagimotoAtsushi IgarashiHidetoshi KokubunShiori MurataNaoki AkagiYuto HattoriYohei AbeNaofumi TsutsumiNoboru ShibasakiMutsushi KawakitaPublished in: International journal of urology : official journal of the Japanese Urological Association (2024)
Dose compliance with estramustine phosphate predicted biochemical recurrence in patients with very high-risk prostate cancer undergoing robot-assisted radical prostatectomy with neoadjuvant chemohormonal therapy.